Literature DB >> 9156649

Effects of CD40 stimulation in the prevention of human EBV-lymphomagenesis.

S Funakoshi1, D D Taub, O Asai, A Hirano, F W Ruscetti, D L Longo, W J Murphy.   

Abstract

CD40 is a molecule present on B lineage cells, both normal and neoplastic. Signalling through CD40 has been demonstrated to promote B cell growth and differentiation in vitro. In contrast to its effects on normal B cells, we have found that CD40 stimulation can inhibit the growth of various aggressive histology human B cell lymphomas both in vitro and in vivo. Moreover, using a human/mouse chimera model in which human EBV-induced B cell lymphomas can spontaneously arise, we have found that CD40 stimulation an prevent the occurrence of this human lymphoma in mice. However, normal human B cell engraftment and function was not adversely affected in these mice by CD40 stimulation. This indicates that CD40 stimulation is selective in its effects on aggressive histology B cell lymphomas. Thus, CD40 stimulation either by antibody or a recombinant soluble ligand, may be of potential clinical use, not only in the treatment of EBV-induced B cell lymphomas, but also in their prevention.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9156649     DOI: 10.3109/10428199709039007

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


  3 in total

1.  Differential signaling and tumor necrosis factor receptor-associated factor (TRAF) degradation mediated by CD40 and the Epstein-Barr virus oncoprotein latent membrane protein 1 (LMP1).

Authors:  K D Brown; B S Hostager; G A Bishop
Journal:  J Exp Med       Date:  2001-04-16       Impact factor: 14.307

Review 2.  Growth and survival of B-chronic lymphocytic leukaemia cells.

Authors:  O Söderberg
Journal:  Med Oncol       Date:  1998-07       Impact factor: 3.064

3.  CD40 ligation prevents Trypanosoma cruzi infection through interleukin-12 upregulation.

Authors:  D Chaussabel; F Jacobs; J de Jonge; M de Veerman; Y Carlier; K Thielemans; M Goldman; B Vray
Journal:  Infect Immun       Date:  1999-04       Impact factor: 3.441

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.